Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Viatris (VTRS)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Boston Scientific (BSX – Research Report) and Viatris (VTRS – Research Report) with bullish sentiments.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Boston Scientific (BSX)
Bank of America Securities analyst Travis Steed maintained a Buy rating on Boston Scientific yesterday and set a price target of $105.00. The company’s shares closed last Friday at $76.27.
According to TipRanks.com, Steed is a 4-star analyst with an average return of
Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $108.14, representing a 40.0% upside. In a report issued on January 26, Evercore ISI also initiated coverage with a Buy rating on the stock with a $112.00 price target.
See today’s best-performing stocks on TipRanks >>
Viatris (VTRS)
According to TipRanks.com, Verma is a 4-star analyst with an average return of
Viatris has an analyst consensus of Moderate Buy, with a price target consensus of $13.60.
